Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 0328 • ACR Convergence 2024
IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Melissa Leeolou¹, Lorinda Chung², Kavita Sarin³ and david fiorentino⁴, ¹Stanford University School of Medicine, Redwood City, CA, ²Stanford University, Woodside, CA, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA
Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity. Melanoma differentiation-associated gene 5…
Abstract Number: 0732 • ACR Convergence 2024
Antineutrophil Cytoplasmic Antibodies and Associated Vasculitis According to Clinical Phenotypes: A Single-Center Retrospective Cohort Study
Mireia Lucía Sanmartín Martínez¹, Roxana González Mazario², Pablo Martínez Calabuig³, Laura Salvador Maicas⁴, Iván Jesús Lorente Betanzos¹, Jorge Juan Fragío Gil⁵, Clara Molina Almela¹, Amalia Rueda², juan José Lerma Garrido⁶, Antonio Sierra Rivera⁷ and Cristina Campos Fernández⁸, ¹Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ²Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ³HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ⁴Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, ⁵Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ⁶Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Hospital General Valencia, Valencia, Spain, ⁸Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a heterogeneous group of rare diseases characterized by necrotizing inflammation predominantly of small vessels, with the presence…
Abstract Number: 1168 • ACR Convergence 2024
Improved Survival in Patients with Myositis-Associated Interstitial Lung Disease (ILD) During the Period 2011 to 2023: Comparative and Integrative Analysis of Three Multicenter Cohorts in Japan
Masataka Kuwana¹, Kenichi Masui², Atsushi Kawakami³, Takafumi Suda⁴, Shinji Sato⁵, Yasushi Kawaguchi⁶, Takeshi Johkoh⁷, Tomoaki Hoshino⁸, Naoki Shimada⁹, Yasuhiro Kondoh¹⁰, Yoshinori Tanino¹¹, Tohru Takeuchi¹², Yoshiyuki Abe¹³, Naoki Kimura¹⁴, Yasushi Inoue¹⁵, Keisuke Tomii¹⁶, Toru Arai¹⁷, Kunihiro Yamaoka¹⁸, Kaneshige Sasaki¹⁹, Taio Naniwa²⁰, Ran Nakashima²¹, Kenjiro Shima²², Osamu Nishiyama²³, Yuko Waseda²⁴, Hiroshi Mukae²⁵, Hirofumi Chiba²⁶, Keigo Ikeda²⁷, Kazuya Ichikado²⁸, Yohei Kirino², Koichi Amano²⁹, Takashi Nawata³⁰, Tomoo Kishaba³¹, Daisuke Asatori³², Daisuke Kobayashi²² and Takahisa Gono³³, ¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ²Yokohama City University School of Medicine, Yokohama, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁵Tokai University School of Medicine, Isehara, Japan, ⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁷Kansai Rosai Hospital, Amagasaki, Japan, ⁸Kurume University School of Medicine, Kurume, Japan, ⁹International University of Health and Welfare, Ohtawara, Japan, ¹⁰Tosei General Hospital, Seto, Japan, ¹¹Fukushima Medical University School of Medicine, Fukushima, Japan, ¹²Osaka Medical and Pharmaceutical University, Takatsuki, Japan, ¹³Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan, ¹⁶Kobe City Medical Center General Hospital, Kobe, Japan, ¹⁷NHO Kinki Chuo Chest Medical Center, Sakai, Japan, ¹⁸Kitasato University School of Medicine, Sagamihara, Japan, ¹⁹Kainan Hospital, Yatomi, Japan, ²⁰Nagoya City University, Nagoya, Japan, ²¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²²Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ²³Kindai University Faculty of Medicine, Osakasayama, Japan, ²⁴University of Fukui, Eiheiji, Japan, ²⁵Nagasaki University Hospital, Nagasaki, Japan, ²⁶Sapporo Medical University, Sapporo, Japan, ²⁷Juntendo University Urayasu Hospital, Urayasu, Japan, ²⁸Saiseikai Kumamoto Hospital, Kumamoto, Japan, ²⁹Saitama Medical Centre, Saitama Medical University, Kawagoe, Japan, ³⁰Yamaguchi University Graduate School of Medicine, Ube, Japan, ³¹Okinawa Chubu Hospital, Uruma, Japan, ³²Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ³³Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: ILD is the leading cause of mortality in patients with idiopathic inflammatory myopathies, and rapidly progressive ILD, associated mainly with anti-MDA5 antibody, is the…
Abstract Number: 1645 • ACR Convergence 2024
Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells
Maria Casal-Dominguez¹, Iago Pinal-Fernandez², Sandra Muñoz-braceras³, Corinna preuße⁴, katherine Pak¹, Jiram Torres Ruiz⁵, Jon Musai¹, Stefania Dell'Orso⁶, Faiza Naz⁶, Shamima Islam², Gusatavo Gutierrez-Cruz², Albert Selva-O’Callaghan⁷, jose milisenda⁸, Werner Stenzel⁹ and Andrew Mammen², ¹National Institutes of health, Bethesda, MD, ²NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁷Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁸Hospital Clinic de Barcelona, Barcelona, Spain, ⁹Charite University, Berlin, Germany
Background/Purpose: Antisynthetase syndrome (AS) is type of myositis characterized by autoantibodies targeting aminoacyl-transfer tRNA synthetases (aaRSs), the enzymes responsible for loading the appropriate amino acid…
Abstract Number: 1930 • ACR Convergence 2024
Clinical Significance of Positive ENA Testing in ANA-Negative Patients: A Retrospective Analysis of Rheumatologic Diagnoses
Bassel Bou Dargham¹, Jason Huang² and Michael Luggen³, ¹University of Cincinnati Medical Center, Cincinnati, OH, ²University of Cincinnati, Cincinnati, ³University Hospital/University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: On the basis of consensus methodology and literature review, the ACR has recommended that antibodies to extractable nuclear antigens (ENA), also known as subserologies…
Abstract Number: 2384 • ACR Convergence 2024
Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
Ranjan Gupta¹, Sonam Rajput², Rudra Prosad Goswami², Jayanth Kumar² and Amita Aggarwal³, ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Autoantibodies in SLE can be detected by either immunoblot assay or by ELISA. Both these methods may have variable performance with respect to the…
Abstract Number: 0040 • ACR Convergence 2024
Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Gary Sims¹, Mia Collins², Natalie Pursell³, Teneema Kuriakose¹, Fanyi Jiang⁴, Kristi Moore⁵, Lucie Bertrand⁵, Melissa Lasaro⁵, Jessica Neisen⁶, Scott Manetz⁷, Gabriel Wong⁸, Patrick Riley⁵, Iain McInnes⁹, Kyriakos Konstantinidis¹⁰ and David Close⁸, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Dicerna, Lexington, ⁴Translation and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁵Alexion, AstraZeneca Rare Disease, New Haven, CT, ⁶Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁷Clinical Pharmacology and Safety Science, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁸Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁹University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹⁰Projects, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: New precision medicine guided therapies targeting alternate disease driving processes are required to improve clinical outcomes in RA. The complement pathway has long been…
Abstract Number: 0341 • ACR Convergence 2024
Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease
Kaito Aoki¹, Keigo Shimura¹, Toshiki Ohisa¹, Akira Ishii¹, Mai Sugiyama², Yuichiro Ota¹, Ayumi Nishikawa³, Noriko Sasaki³, Chiho Yamada¹ and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Japan, ²Tokai University, Isehara, Japan, ³Tokai University Hachioji Hospital, Hachioji, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders that affect muscle, skin and lung to varying degrees. Interstitial lung disease (ILD) is a major…
Abstract Number: 0750 • ACR Convergence 2024
Corticosteroid Withdrawal Using Tocilizumab and Its Association with Autoantibody Profile in Takayasu Arteritis: A Multicenter, Single-arm, Prospective Study
Tsuyoshi Shirai¹, Tomonori Ishii², Soshi Okazaki¹, Yuko Shirota³, Yusho Ishii⁴, Hiroko Sato¹ and Hiroshi Fujii¹, ¹Tohoku University, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ³Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ⁴Tohoku university, Sendai, Miyagi, Japan
Background/Purpose: The application of molecular targeted drugs has been expanding in vasculitides. Takayasu arteritis (TAK) frequently relapses and tocilizumab (TCZ) and tumor necrosis factor inhibitors…
Abstract Number: 1295 • ACR Convergence 2024
A Qualitative Survey of Internal Medicine Residents’ Understanding of Appropriate ANA Testing: An 11-Year Update Since the ‘Choosing Wisely’ Campaign
Arushika Yedla¹, Wei Tang², Jaspreet Bhatti², Kyu-In Lee³ and James Miceli³, ¹Westchester Medical Center, White Plains, NY, ²Westchester Medical Center, Valhalla, ³Westchester Medical Center, Valhalla, NY
Background/Purpose: ANA testing is recommended when there is a reasonable clinical suspicion for systemic autoimmune disease. Testing in the setting of low pre-test probability, however,…
Abstract Number: 1649 • ACR Convergence 2024
B Cell Subset Contribution to Autoantibodies in Lupus
Kristina Ottens¹, Jalyn Schneider¹ and Anne Satterthwaite², ¹UT Southwestern Medical Center, Dallas, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic lupus erythematous is characterized by the production of pathogenic autoantibodies that drive inflammation and tissue damage. Defining the B cell subsets that give…
Abstract Number: 2052 • ACR Convergence 2024
Role of Scleroderma/myositis-related Autoantibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 410 Patients from a Single Referral Center
Carmen Secada Gómez¹, Diana Prieto-Peña², Mónica Renuncio-García³, Juan Irure-Ventura⁴, Marcos Lopez-Hoyos⁵ and Ricardo Blanco-Alonso⁶, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁴Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Cantabria, Spain, ⁵Division of Immunology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: In clinical practice, immunoblot assays are being used more frequently as a diagnostic tool for systemic autoimmune rheumatic diseases (SARDs).Our aim was to evaluate the…
Abstract Number: 2391 • ACR Convergence 2024
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Güllü Sandal Uzun¹, Emily Apsley² and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: The anti-nuclear antibody (ANA test) is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
Abstract Number: 0048 • ACR Convergence 2024
Role of the Chemokine CCL22 in Rheumatoid Arthritis Development
Marcelo Afonso¹, Masa Filipovic¹, Alexandra Argyriou², Alexandra Circiumaru³, Mikael Ringh¹, Konstantin Carlberg¹, Vijay Joshua¹, Szu-Jing Chen¹, Marianne Engström¹, Heidi Wähämaa¹, Tomas Ekström¹, Marc H Wadsworth II⁴, Ravi Kumar¹, Aaron Winkler⁵, Vivianne Malmström¹, Anca Catrina¹, Karine Chemin¹, Aase Hensvold¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Solna, Sweden, ³Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden, ⁴Pfizer, Cambridge, ⁵Pfizer Inc., Cambridge, MA
Background/Purpose: Understanding alterations of the immune homeostasis in individuals at risk of rheumatoid arthritis (RA) can be a key to achieve earlier diagnosis and prevention.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].